These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 39018203)

  • 1. Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval.
    Aus dem Siepen F; Meissner C; Hofmann E; Hein S; Nagel C; Hegenbart U; Schönland SO; Andre F; Frey N; Kristen AV
    Amyloid; 2024 Sep; 31(3):226-231. PubMed ID: 39018203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
    Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
    Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
    [No Abstract]   [Full Text] [Related]  

  • 5. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN; Deeks ED
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.
    Rettl R; Mann C; Duca F; Dachs TM; Binder C; Ligios LC; Schrutka L; Dalos D; Koschutnik M; Donà C; Kammerlander A; Beitzke D; Loewe C; Charwat-Resl S; Hengstenberg C; Kastner J; Eslam RB; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2022 Jun; 23(6):767-780. PubMed ID: 34788394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.
    Tess DA; Maurer TS; Li Z; Bulawa C; Fleming J; Moody AT
    Amyloid; 2023 Jun; 30(2):208-219. PubMed ID: 36399070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
    Capovilla TM; Lalario A; Rossi M; Porcari A; Aimo A; Limongelli G; Emdin M; Merlo M; Sinagra G
    Heart Fail Clin; 2024 Jul; 20(3):333-341. PubMed ID: 38844304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study.
    Garcia-Pavia P; Sultan MB; Gundapaneni B; Sekijima Y; Perfetto F; Hanna M; Witteles R
    JACC Heart Fail; 2024 Jan; 12(1):150-160. PubMed ID: 37943223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
    Rettl R; Wollenweber T; Duca F; Binder C; Cherouny B; Dachs TM; Camuz Ligios L; Schrutka L; Dalos D; Beitzke D; Loewe C; Badr Eslam R; Kastner J; Hacker M; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2023 Jul; 24(8):1019-1030. PubMed ID: 36881774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy.
    Kuyama N; Takashio S; Oguni T; Yamamoto M; Hirakawa K; Ishii M; Hanatani S; Oda S; Matsuzawa Y; Usuku H; Yamamoto E; Hirai T; Ueda M; Tsujita K
    J Am Heart Assoc; 2024 May; 13(10):e034518. PubMed ID: 38761073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin.
    Dobner S; Bernhard B; Asatryan B; Windecker S; Stortecky S; Pilgrim T; Gräni C; Hunziker L
    ESC Heart Fail; 2023 Feb; 10(1):397-404. PubMed ID: 36259276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tafamidis on left atrial function of patients with transthyretin amyloid cardiomyopathy.
    Uemura K; Ichikawa Y; Nagai S; Nishihara Y; Todo S; Oota E; Odajima S; Takeuchi K; Kintsu M; Fukuda T; Hisamatsu E; Hirata KI; Tanaka H
    Heart Vessels; 2024 Sep; 39(9):810-817. PubMed ID: 38743105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
    Patil MB; Ghode P; Joshi P
    Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
    Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
    Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Tafamidis in Patients with Ala97Ser Hereditary Transthyretin Cardiac Amyloidosis: A Six-Month Follow-Up Study.
    Tsai CH; Yu AL; Wu YA; Su MY; Cheng MF; Chou CH; Shun CT; Hsueh HW; Juang JJ; Lee MJ; Tseng PH; Hsieh ST; Chao CC; Lin YH
    Acta Cardiol Sin; 2023 Jul; 39(4):619-627. PubMed ID: 37456942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A; Vita G; Luigetti M; Russo M; Bisogni G; Sabatelli M; Manganelli F; Santoro L; Cavallaro T; Fabrizi GM; Schenone A; Grandis M; Gemelli C; Mauro A; Pradotto LG; Gentile L; Stancanelli C; Lozza A; Perlini S; Piscosquito G; Calabrese D; Mazzeo A; Obici L; Pareyson D
    J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
    Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
    Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study.
    Tsai CH; Chao CC; Hsieh ST; Yu AL; Wu YA; Cheng MF; Lee MJ; Chou CH; Shun CT; Hsueh HW; Jyh-Ming Juang J; Tseng PH; Su MY; Lin YH
    Orphanet J Rare Dis; 2023 Sep; 18(1):289. PubMed ID: 37705003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.